

Table 1. Clinical characteristics of the study cohort (n=252)

Clinical characteristics	n (%)
Age at diagnosis (Range:25-82, median=52)	
≤45 years	83 (32.9)
>45 years	169 (67.1)
Primary T stage	
I	59 (23.4)
II	122 (48.5)
III	22 (8.7)
IV	28 (11.1)
Unknown	21 (8.3)
Primary N stage	
0	64 (25.4)
1	59 (23.4)
2	47 (18.7)
3	67 (26.6)
Unknown	15 (5.9)
Primary TNM stage	
I	23 (9.1)
II	73 (28.7)
III	76 (30.2)
IV	67 (26.9)
Unknown	13 (5.1)
Primary tumor grade	
I	5 (1.9)
II	144 (57.1)
III	68 (27.0)
Unknown	35 (14.0)
Liver metastasis	
No	159 (63.1)
Yes	93 (36.9)
Lung metastasis	
No	155 (61.5)
Yes	97 (38.5)
Brain metastasis	
No	240 (95.2)
Yes	12 (4.8)

Bone metastasis	
No	159 (63.1)
Yes	93 (36.9)
Lymph metastasis	
No	92 (36.5)
Yes	160 (63.5)
Chest wall metastasis	
No	211 (83.7)
Yes	41 (16.3)
Uncommon metastasis^a	
No	219 (86.9)
Yes	33 (13.1)
Visceral metastasis^b	
No	89 (35.3)
Yes	163 (64.7)
Number of metastatic sites^c	
1	90 (35.7)
2-3	132 (52.4)
≥4	30 (11.9)
Disease free survival (Range:3-283, median=32)	
≤36 months	104 (56.2)
>36 months	81 (43.8)
Regimens of first-line therapy	
Chemotherapy plus trastuzumab	151 (60.0)
Chemotherapy plus trastuzumab & pertuzumab	49 (19.4)
Chemotherapy plus TKIs ^d	23 (9.1)
Chemotherapy alone	29 (11.5)

^aUncommon metastasis including pleural, adrenal, cutaneous, intestinal and soft tissue metastasis.

^bVisceral metastasis include the lung, liver and brain.

^cMultiple lesions occurred in the same organ only count once.

^dTyrosine kinase inhibitors